EW

Edwards Lifesciences Corporation

$104.01

-0.67%
SectorHealthcareIndustryMedical DevicesCountryUnited States

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Source: Yahoo Finance
AI summary

Price & performance

1M+15.6%
3M+13.3%
YTD+18.2%
1Y+21.7%
52-week range—
Beta0.58
Full chart and returns against a benchmark

Q-Score

69/ 100

Quality against peers; 50 is the peer median.

Growth57
Risk81
Performance57
Valuation46
Profitability69
Leverage81
Sentiment64
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$6.1B+11.5%
Net income$1.1B-74.3%
Net margin17.7%-59.1 pts
Historical fundamentals

Revenue exposure

42%of revenue from outside the US
United States58%
Europe25%
Rest Of World11%
Regions, segments, customers and suppliers

Valuation

EWIndustryP/E58.5629.61P/S8.963.49EV/EBITDA35.5418.38P/B5.513.39PEG——
Dividend yield0.00%
Every valuation metric

Earnings

Nov 4next report
EPS estimate$0.74
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate